SIDA E INFECCIONES VIH

Foto de SIDA E INFECCIONES VIH

Foto de Université Denis Diderot

Université Denis Diderot

París, Francia

Publications en collaboration avec des chercheurs de Université Denis Diderot (4)

2019

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
Antiviral Research, Vol. 170

2018

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
The Lancet HIV, Vol. 5, Núm. 1, pp. e23-e34
Prosthetic Valve Candida spp. Endocarditis: New Insights into Long-term Prognosis-The ESCAPE Study
Clinical Infectious Diseases, Vol. 66, Núm. 6, pp. 825-832

2016

Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe
Clinical Infectious Diseases, Vol. 62, Núm. 5, pp. 655-663